Chemicals
Showing 34051–34200 of 41137 results
-
Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524 (Item No. 30469).{45842,45860} Upon entry into cells, remdesivir is metabolized into a nucleoside monophosphate form, which is further metabolized to an active nucleoside triphosphate that induces RNA chain termination and inhibits viral polymerases.{52859} Remdesivir reduces viral titers in primary human airway epithelial (HAE) cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively). It reduces infectious virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).{61140} In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a mouse model of SARS-CoV infection.{45860} Remdesivir (25 mg/kg) also reduces lung viral titers and lung hemorrhage and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).{61140} Formulations containing remdesivir have been used in the treatment of COVID-19.
Brand:CaymanSKU:30354 - 100 mgAvailable on backorder
Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524 (Item No. 30469).{45842,45860} Upon entry into cells, remdesivir is metabolized into a nucleoside monophosphate form, which is further metabolized to an active nucleoside triphosphate that induces RNA chain termination and inhibits viral polymerases.{52859} Remdesivir reduces viral titers in primary human airway epithelial (HAE) cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively). It reduces infectious virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).{61140} In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a mouse model of SARS-CoV infection.{45860} Remdesivir (25 mg/kg) also reduces lung viral titers and lung hemorrhage and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).{61140} Formulations containing remdesivir have been used in the treatment of COVID-19.
Brand:CaymanSKU:30354 - 5 mgAvailable on backorder
Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524 (Item No. 30469).{45842,45860} Upon entry into cells, remdesivir is metabolized into a nucleoside monophosphate form, which is further metabolized to an active nucleoside triphosphate that induces RNA chain termination and inhibits viral polymerases.{52859} Remdesivir reduces viral titers in primary human airway epithelial (HAE) cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively). It reduces infectious virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).{61140} In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a mouse model of SARS-CoV infection.{45860} Remdesivir (25 mg/kg) also reduces lung viral titers and lung hemorrhage and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).{61140} Formulations containing remdesivir have been used in the treatment of COVID-19.
Brand:CaymanSKU:30354 - 50 mgAvailable on backorder
Remifentanil acid (trifluoroacetate salt) (Item No. 21926) is an analytical reference standard categorized as an opioid.{35117} It is a known active metabolite of remifentanil (Item No. 19291).{34409} This product is intended for research and forensic applications.
Brand:CaymanSKU:21926 -Out of stock
Remifentanil acid (trifluoroacetate salt) (Item No. 21926) is an analytical reference standard categorized as an opioid.{35117} It is a known active metabolite of remifentanil (Item No. 19291).{34409} This product is intended for research and forensic applications.
Brand:CaymanSKU:21926 -Out of stock
Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:-Available on backorder
Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:-Available on backorder
Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:-Available on backorder
Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:-Available on backorder
Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:- Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:- Progeria is a genetic disorder that results in the appearance of premature aging. Genetically, progeria is characterized by a mutation in lamin A, which results in misshapen cell nuclei and DNA damage. Remodelin is a 2-thiazolylhydrazone derivative that, at 10 µM, improves nuclear architecture, chromatin organization, and survival of both cells lacking lamin A and cells from patients with progeria.{26026} Remodelin is an inhibitor of N-acetyltransferase 10 (NAT10), which acetylates both histones and microtubules.{26026} Mutation of NAT10 mimics the effects of remodelin on nuclear morphology, suggesting that these effects of remodelin require NAT10.{26026} Remodelin also has cytotoxic effects against some species of the fungus Candida.{25935}
Brand:CaymanSKU:-
Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively).{41327} It is selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A in vivo, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin (Item No. 13104) and db/db mice with hyperinsulinemia and obesity.
Brand:CaymanSKU:- Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively).{41327} It is selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A in vivo, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin (Item No. 13104) and db/db mice with hyperinsulinemia and obesity.
Brand:CaymanSKU:- Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively).{41327} It is selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A in vivo, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin (Item No. 13104) and db/db mice with hyperinsulinemia and obesity.
Brand:CaymanSKU:- Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively).{41327} It is selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A in vivo, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin (Item No. 13104) and db/db mice with hyperinsulinemia and obesity.
Brand:CaymanSKU:-
Remogliflozin etabonate is a prodrug form of the sodium-glucose transporter 2 (SGLT2) inhibitor remogliflozin A (Item No. 14340).{41327} Remogliflozin etabonate inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively). It inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) when administered at doses of 3 and 10 mg/ml. Remogliflozin etabonate (10 and 30 mg/kg twice per day for 6 weeks) also increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity.
Brand:CaymanSKU:- Remogliflozin etabonate is a prodrug form of the sodium-glucose transporter 2 (SGLT2) inhibitor remogliflozin A (Item No. 14340).{41327} Remogliflozin etabonate inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively). It inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) when administered at doses of 3 and 10 mg/ml. Remogliflozin etabonate (10 and 30 mg/kg twice per day for 6 weeks) also increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity.
Brand:CaymanSKU:-
Remoxipride is an atypical antipsychotic and dopamine D2 receptor antagonist (Ki = 0.2 µM).{58006} It is selective for the dopamine D2 receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 µM but does inhibit the sigma (σ) receptor (Ki = 0.065 µM). Remoxipride (2-20 µmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.{58007} It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED50 values of 5.6 and 0.8 µmol/kg, respectively.{58008} Formulations containing remoxipride have previously been used in the treatment of schizophrenia.
Brand:CaymanSKU:30971 - 1 mgAvailable on backorder
Remoxipride is an atypical antipsychotic and dopamine D2 receptor antagonist (Ki = 0.2 µM).{58006} It is selective for the dopamine D2 receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 µM but does inhibit the sigma (σ) receptor (Ki = 0.065 µM). Remoxipride (2-20 µmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.{58007} It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED50 values of 5.6 and 0.8 µmol/kg, respectively.{58008} Formulations containing remoxipride have previously been used in the treatment of schizophrenia.
Brand:CaymanSKU:30971 - 10 mgAvailable on backorder
Remoxipride is an atypical antipsychotic and dopamine D2 receptor antagonist (Ki = 0.2 µM).{58006} It is selective for the dopamine D2 receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 µM but does inhibit the sigma (σ) receptor (Ki = 0.065 µM). Remoxipride (2-20 µmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.{58007} It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED50 values of 5.6 and 0.8 µmol/kg, respectively.{58008} Formulations containing remoxipride have previously been used in the treatment of schizophrenia.
Brand:CaymanSKU:30971 - 5 mgAvailable on backorder
Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).{32299} In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).{32300} Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
Brand:CaymanSKU:-Available on backorder
Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).{32299} In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).{32300} Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
Brand:CaymanSKU:-Available on backorder
Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).{32299} In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).{32300} Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
Brand:CaymanSKU:-Available on backorder
Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).{32299} In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).{32300} Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
Brand:CaymanSKU:-Available on backorder
Repaglinide-d5 is intended for use as an internal standard for the quantification of repaglinide (Item No. 19387) by GC- or LC-MS. Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).{32299} In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).{32300} Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
Brand:CaymanSKU:26104 - 1 mgAvailable on backorder
Repaglinide-d5 is intended for use as an internal standard for the quantification of repaglinide (Item No. 19387) by GC- or LC-MS. Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).{32299} In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).{32300} Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
Brand:CaymanSKU:26104 - 500 µgAvailable on backorder
Reparixin is a non-competitive allosteric inhibitor of the activation of CXCR1 and CXCR2 chemokine receptors by IL-8 (IC50s = 1 and 100 nM, respectively).{28557} It blocks a range of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) and other inflammatory responses, without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.{28557} In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks reduces blood pressure by inhibiting hypertension-related mediators, IL-8, 12-lipoxygenase, and endothelin-1.{28553} Reparixin blockade (100 nM) of CXCR1 depletes a cancer stem cell population in human breast cancer cell lines in vitro.{28554}
Brand:CaymanSKU:21492 -Out of stock
Reparixin is a non-competitive allosteric inhibitor of the activation of CXCR1 and CXCR2 chemokine receptors by IL-8 (IC50s = 1 and 100 nM, respectively).{28557} It blocks a range of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) and other inflammatory responses, without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.{28557} In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks reduces blood pressure by inhibiting hypertension-related mediators, IL-8, 12-lipoxygenase, and endothelin-1.{28553} Reparixin blockade (100 nM) of CXCR1 depletes a cancer stem cell population in human breast cancer cell lines in vitro.{28554}
Brand:CaymanSKU:21492 -Out of stock
Reparixin is a non-competitive allosteric inhibitor of the activation of CXCR1 and CXCR2 chemokine receptors by IL-8 (IC50s = 1 and 100 nM, respectively).{28557} It blocks a range of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) and other inflammatory responses, without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.{28557} In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks reduces blood pressure by inhibiting hypertension-related mediators, IL-8, 12-lipoxygenase, and endothelin-1.{28553} Reparixin blockade (100 nM) of CXCR1 depletes a cancer stem cell population in human breast cancer cell lines in vitro.{28554}
Brand:CaymanSKU:21492 -Out of stock
Reparixin is a non-competitive allosteric inhibitor of the activation of CXCR1 and CXCR2 chemokine receptors by IL-8 (IC50s = 1 and 100 nM, respectively).{28557} It blocks a range of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) and other inflammatory responses, without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.{28557} In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks reduces blood pressure by inhibiting hypertension-related mediators, IL-8, 12-lipoxygenase, and endothelin-1.{28553} Reparixin blockade (100 nM) of CXCR1 depletes a cancer stem cell population in human breast cancer cell lines in vitro.{28554}
Brand:CaymanSKU:21492 -Out of stock
Resazurin is a blue non-fluorescent dye that when reduced to the highly red-fluorescent product resorufin (ex/em max = 570/580 nm, respectively) can be used as a quantifiable detection agent for enzyme activity assays.{22811,53819} The non-fluorescent resazurin can be used as an oxidation-reduction indicator in cell viability assays in a variety of cells.{22811}
Brand:CaymanSKU:- Resazurin is a blue non-fluorescent dye that when reduced to the highly red-fluorescent product resorufin (ex/em max = 570/580 nm, respectively) can be used as a quantifiable detection agent for enzyme activity assays.{22811,53819} The non-fluorescent resazurin can be used as an oxidation-reduction indicator in cell viability assays in a variety of cells.{22811}
Brand:CaymanSKU:- Resazurin is a blue non-fluorescent dye that when reduced to the highly red-fluorescent product resorufin (ex/em max = 570/580 nm, respectively) can be used as a quantifiable detection agent for enzyme activity assays.{22811,53819} The non-fluorescent resazurin can be used as an oxidation-reduction indicator in cell viability assays in a variety of cells.{22811}
Brand:CaymanSKU:-
Reserpiline is an indole alkaloid that has been found in R. tetraphylla.{52748} Oral administration of reserpiline (12.5 and 25 mg/kg) decreases amphetamine-induced hyperactivity, indicating antipsychotic potential, in mice.
Brand:CaymanSKU:31332 - 1 mgAvailable on backorder
Reserpiline is an indole alkaloid that has been found in R. tetraphylla.{52748} Oral administration of reserpiline (12.5 and 25 mg/kg) decreases amphetamine-induced hyperactivity, indicating antipsychotic potential, in mice.
Brand:CaymanSKU:31332 - 5 mgAvailable on backorder
Reserpine is an alkaloid isolated from dried roots of R. serpentine, which is used in traditional Indian medicine. Reserpine irreversibly inhibits both human isoforms of vesicular monoamine transporter, VMAT1 and VMAT2 (Kis = 34 and 12 nM, respectively).{26972,26973} As this leads to metabolism of monoamines, reserpine is used to experimentally deplete monoamines in animals.{26970,26971,20200} Reserpine also inhibits the multidrug resistance protein P-glycoprotein (IC50 = 0.5 µM).{25345}
Brand:CaymanSKU:-Out of stock
Reserpine is an alkaloid isolated from dried roots of R. serpentine, which is used in traditional Indian medicine. Reserpine irreversibly inhibits both human isoforms of vesicular monoamine transporter, VMAT1 and VMAT2 (Kis = 34 and 12 nM, respectively).{26972,26973} As this leads to metabolism of monoamines, reserpine is used to experimentally deplete monoamines in animals.{26970,26971,20200} Reserpine also inhibits the multidrug resistance protein P-glycoprotein (IC50 = 0.5 µM).{25345}
Brand:CaymanSKU:-Out of stock
Resibufogenin is a cardiac glycoside first isolated from Bufonis venom that acts as an inhibitor of the Na+/K+-ATPase.{32254} It exhibits cardiotonic, vasopressor, and respiratory stimulating actions in both animal and clinical models.{32253} Resibufogenin has been used to antagonize the action of marinobufagenin in a rat experimental model of preeclampsia.{32255} Resibufogenin is also reported to have antiproliferative effects against cancer cells, inducing cell cycle arrest by suppressing the expression of cyclin D1.{32252}
Brand:CaymanSKU:9001348 - 1 mgAvailable on backorder
Resibufogenin is a cardiac glycoside first isolated from Bufonis venom that acts as an inhibitor of the Na+/K+-ATPase.{32254} It exhibits cardiotonic, vasopressor, and respiratory stimulating actions in both animal and clinical models.{32253} Resibufogenin has been used to antagonize the action of marinobufagenin in a rat experimental model of preeclampsia.{32255} Resibufogenin is also reported to have antiproliferative effects against cancer cells, inducing cell cycle arrest by suppressing the expression of cyclin D1.{32252}
Brand:CaymanSKU:9001348 - 10 mgAvailable on backorder
Resibufogenin is a cardiac glycoside first isolated from Bufonis venom that acts as an inhibitor of the Na+/K+-ATPase.{32254} It exhibits cardiotonic, vasopressor, and respiratory stimulating actions in both animal and clinical models.{32253} Resibufogenin has been used to antagonize the action of marinobufagenin in a rat experimental model of preeclampsia.{32255} Resibufogenin is also reported to have antiproliferative effects against cancer cells, inducing cell cycle arrest by suppressing the expression of cyclin D1.{32252}
Brand:CaymanSKU:9001348 - 5 mgAvailable on backorder
Resibufogenin is a cardiac glycoside first isolated from Bufonis venom that acts as an inhibitor of the Na+/K+-ATPase.{32254} It exhibits cardiotonic, vasopressor, and respiratory stimulating actions in both animal and clinical models.{32253} Resibufogenin has been used to antagonize the action of marinobufagenin in a rat experimental model of preeclampsia.{32255} Resibufogenin is also reported to have antiproliferative effects against cancer cells, inducing cell cycle arrest by suppressing the expression of cyclin D1.{32252}
Brand:CaymanSKU:9001348 - 50 mgAvailable on backorder
Resistoflavine is a metabolite of the marine actinomycete S. chibaensis.{35222} It slows the growth of and is cytotoxic to HMO2 and HepG2 cells with mean lethal concentrations (LC50) of 0.013 and 0.016 µg/ml, respectively.
Brand:CaymanSKU:24178 - 1 mgAvailable on backorder
Resistoflavine is a metabolite of the marine actinomycete S. chibaensis.{35222} It slows the growth of and is cytotoxic to HMO2 and HepG2 cells with mean lethal concentrations (LC50) of 0.013 and 0.016 µg/ml, respectively.
Brand:CaymanSKU:24178 - 5 mgAvailable on backorder
Resistomycin is a natural antibiotic produced by several actinobacteriae, including Streptomyces. Resistomycin, as well as culture broths rich in resistomycin, have antioxidant activity, modulate apoptosis, and can be cytotoxic against cancer cell lines.{32271,32272} Resistomycin also has activity against HIV-1 protease.{32270}
Brand:CaymanSKU:20685 -Available on backorder
Resistomycin is a natural antibiotic produced by several actinobacteriae, including Streptomyces. Resistomycin, as well as culture broths rich in resistomycin, have antioxidant activity, modulate apoptosis, and can be cytotoxic against cancer cell lines.{32271,32272} Resistomycin also has activity against HIV-1 protease.{32270}
Brand:CaymanSKU:20685 -Available on backorder
Resminostat is an orally bioavailable inhibitor of histone deacetylase 1 (HDAC1), HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells.{29101} It abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM).{29101} Resminostat displays synergistic effects when combined with melphalan and the proteasome inhibitors bortezomib and S-2209.{29101} It dose-dependently inhibits HDAC activity in vivo.{29100}
Brand:CaymanSKU:-Available on backorder
Resminostat is an orally bioavailable inhibitor of histone deacetylase 1 (HDAC1), HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells.{29101} It abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM).{29101} Resminostat displays synergistic effects when combined with melphalan and the proteasome inhibitors bortezomib and S-2209.{29101} It dose-dependently inhibits HDAC activity in vivo.{29100}
Brand:CaymanSKU:-Available on backorder
Resminostat is an orally bioavailable inhibitor of histone deacetylase 1 (HDAC1), HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells.{29101} It abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM).{29101} Resminostat displays synergistic effects when combined with melphalan and the proteasome inhibitors bortezomib and S-2209.{29101} It dose-dependently inhibits HDAC activity in vivo.{29100}
Brand:CaymanSKU:-Available on backorder
Resminostat is an orally bioavailable inhibitor of histone deacetylase 1 (HDAC1), HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells.{29101} It abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM).{29101} Resminostat displays synergistic effects when combined with melphalan and the proteasome inhibitors bortezomib and S-2209.{29101} It dose-dependently inhibits HDAC activity in vivo.{29100}
Brand:CaymanSKU:-Available on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer (Item No. 13060) of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R)-configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718} Analytical and biological comparisons of synthetic RvD1 with endogenously derived RvD1 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10012554 - 10 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer (Item No. 13060) of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R)-configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718} Analytical and biological comparisons of synthetic RvD1 with endogenously derived RvD1 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10012554 - 100 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer (Item No. 13060) of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R)-configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718} Analytical and biological comparisons of synthetic RvD1 with endogenously derived RvD1 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10012554 - 25 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer (Item No. 13060) of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R)-configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718} Analytical and biological comparisons of synthetic RvD1 with endogenously derived RvD1 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10012554 - 50 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer (Item No. 13060) of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R)-configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718} Analytical and biological comparisons of synthetic RvD1 with endogenously derived RvD1 have confirmed its identity as matching the natural product.{14569} RvD1 MaxSpec® standard is a quantitative grade standard of RvD1 (Item No. 10012554) that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This RvD1 MaxSpec® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.
Brand:CaymanSKU:25905 - 10 µgAvailable on backorder
Resolvin D1 (RvD1; Item No. 10012554) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (Item No. 90310) by 15- and 5-lipoxygenase (Item No. 60402).{13989} It reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with an EC50 value of ~30 nM.{15718} RvD1 methyl ester is a methyl ester version of the free acid that may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001815 - 10 µgAvailable on backorder
Resolvin D1 (RvD1; Item No. 10012554) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (Item No. 90310) by 15- and 5-lipoxygenase (Item No. 60402).{13989} It reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with an EC50 value of ~30 nM.{15718} RvD1 methyl ester is a methyl ester version of the free acid that may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001815 - 100 µgAvailable on backorder
Resolvin D1 (RvD1; Item No. 10012554) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (Item No. 90310) by 15- and 5-lipoxygenase (Item No. 60402).{13989} It reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with an EC50 value of ~30 nM.{15718} RvD1 methyl ester is a methyl ester version of the free acid that may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001815 - 25 µgAvailable on backorder
Resolvin D1 (RvD1; Item No. 10012554) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (Item No. 90310) by 15- and 5-lipoxygenase (Item No. 60402).{13989} It reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with an EC50 value of ~30 nM.{15718} RvD1 methyl ester is a methyl ester version of the free acid that may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001815 - 50 µgAvailable on backorder
Resolvin D1-d5 (RvD1-d5) is intended for use as an internal standard for the quantification of RvD1 (Item No. 10012554) by GC- or LC-mass spectrometry. Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} RvD1 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R) configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718}
Brand:CaymanSKU:11182 - 10 µgAvailable on backorder
Resolvin D1-d5 (RvD1-d5) is intended for use as an internal standard for the quantification of RvD1 (Item No. 10012554) by GC- or LC-mass spectrometry. Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} RvD1 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.{13989} A 17(R)-epimer of RvD1 can also be generated in aspirin-treated samples.{11433} Both RvD1 and its 17(R) configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM.{15718} RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.{15718}
Brand:CaymanSKU:11182 - 25 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.{18209} It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.{18209} Also, by stimulating nitric oxide production, RvD2 dose dependently decreases leukocyte-endothelial interactions. In a mouse model of sepsis, RvD2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.{18209} Analytical and biological comparisons of synthetic RvD2 with endogenously derived RvD2 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10007279 - 10 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.{18209} It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.{18209} Also, by stimulating nitric oxide production, RvD2 dose dependently decreases leukocyte-endothelial interactions. In a mouse model of sepsis, RvD2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.{18209} Analytical and biological comparisons of synthetic RvD2 with endogenously derived RvD2 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10007279 - 100 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.{18209} It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.{18209} Also, by stimulating nitric oxide production, RvD2 dose dependently decreases leukocyte-endothelial interactions. In a mouse model of sepsis, RvD2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.{18209} Analytical and biological comparisons of synthetic RvD2 with endogenously derived RvD2 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10007279 - 25 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.{18209} It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.{18209} Also, by stimulating nitric oxide production, RvD2 dose dependently decreases leukocyte-endothelial interactions. In a mouse model of sepsis, RvD2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.{18209} Analytical and biological comparisons of synthetic RvD2 with endogenously derived RvD2 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:10007279 - 50 µgAvailable on backorder
Resolvin D2 (RvD2) (Item No. 10007279) is a lipid mediator biosynthesized by the sequential oxygenation of docosahexaenoic acid by 15- and 5-lipoxygenase.{20052} It evokes diverse anti-inflammatory effects which may mediate the resolution of inflammation.{19640,18209} RvD2 methyl ester is a methyl ester version of the free acid which may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001497 - 10 µgAvailable on backorder
Resolvin D2 (RvD2) (Item No. 10007279) is a lipid mediator biosynthesized by the sequential oxygenation of docosahexaenoic acid by 15- and 5-lipoxygenase.{20052} It evokes diverse anti-inflammatory effects which may mediate the resolution of inflammation.{19640,18209} RvD2 methyl ester is a methyl ester version of the free acid which may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001497 - 100 µgAvailable on backorder
Resolvin D2 (RvD2) (Item No. 10007279) is a lipid mediator biosynthesized by the sequential oxygenation of docosahexaenoic acid by 15- and 5-lipoxygenase.{20052} It evokes diverse anti-inflammatory effects which may mediate the resolution of inflammation.{19640,18209} RvD2 methyl ester is a methyl ester version of the free acid which may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001497 - 25 µgAvailable on backorder
Resolvin D2 (RvD2) (Item No. 10007279) is a lipid mediator biosynthesized by the sequential oxygenation of docosahexaenoic acid by 15- and 5-lipoxygenase.{20052} It evokes diverse anti-inflammatory effects which may mediate the resolution of inflammation.{19640,18209} RvD2 methyl ester is a methyl ester version of the free acid which may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.
Brand:CaymanSKU:9001497 - 50 µgAvailable on backorder
Resolvin D2-d5 (RvD2-d5) is intended for use as an internal standard for the quantification of resolvin D2 (Item No. 10007279) by GC- or LC-MS. Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D2 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.{18209} It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.{18209} Also, by stimulating nitric oxide production, resolvin D2 dose dependently decreases leukocyte-endothelial interactions. In a murine model of sepsis, resolvin D2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.{18209}
Brand:CaymanSKU:11184 - 10 µgAvailable on backorder
Resolvin D2-d5 (RvD2-d5) is intended for use as an internal standard for the quantification of resolvin D2 (Item No. 10007279) by GC- or LC-MS. Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.{14973} Resolvin D2 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase and functions to dampen excessive neutrophil trafficking to sites of inflammation.{18209} It reduces zymosan-stimulated PMN infiltration by 70% at doses as low as 10 pg per mouse and significantly reduces PAF-stimulated leukocyte adherence and emigration at 1 nM.{18209} Also, by stimulating nitric oxide production, resolvin D2 dose dependently decreases leukocyte-endothelial interactions. In a murine model of sepsis, resolvin D2 reduces leukocyte and PMN infiltration, decreases production of pro-inflammatory cytokines, and promotes phagocyte-mediated bacterial clearance.{18209}
Brand:CaymanSKU:11184 - 25 µgAvailable on backorder
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response.{14973} Resolvin D3 (RvD3) is a DHA-derived product first identified in mouse inflammatory exudates.{11433} It reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation.{11433} In addition to suppressing leukocyte migration, RvD3 enhances macrophage phagocytosis and efferocytosis.{29714} Unlike other resolvins, RvD3 appears late in resolution in mouse peritonitis.{29714,29715} Analytical and biological comparisons of synthetic RvD3 with endogenously derived RvD3 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:- Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response.{14973} Resolvin D3 (RvD3) is a DHA-derived product first identified in mouse inflammatory exudates.{11433} It reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation.{11433} In addition to suppressing leukocyte migration, RvD3 enhances macrophage phagocytosis and efferocytosis.{29714} Unlike other resolvins, RvD3 appears late in resolution in mouse peritonitis.{29714,29715} Analytical and biological comparisons of synthetic RvD3 with endogenously derived RvD3 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:- Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response.{14973} Resolvin D3 (RvD3) is a DHA-derived product first identified in mouse inflammatory exudates.{11433} It reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation.{11433} In addition to suppressing leukocyte migration, RvD3 enhances macrophage phagocytosis and efferocytosis.{29714} Unlike other resolvins, RvD3 appears late in resolution in mouse peritonitis.{29714,29715} Analytical and biological comparisons of synthetic RvD3 with endogenously derived RvD3 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:- Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).{13989} In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response.{14973} Resolvin D3 (RvD3) is a DHA-derived product first identified in mouse inflammatory exudates.{11433} It reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation.{11433} In addition to suppressing leukocyte migration, RvD3 enhances macrophage phagocytosis and efferocytosis.{29714} Unlike other resolvins, RvD3 appears late in resolution in mouse peritonitis.{29714,29715} Analytical and biological comparisons of synthetic RvD3 with endogenously derived RvD3 have confirmed its identity as matching the natural product.{14569}
Brand:CaymanSKU:-
Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid (Item No. 90310).{18022} It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.{32237,30353} RvD4, at 10 ng/mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng/mouse, diminishes neutrophil infiltration in response to S. aureus infection.{30353} With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.{30353} It also promotes the clearance of apoptotic neutrophils by human fibroblasts.{30353}
Brand:CaymanSKU:- Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid (Item No. 90310).{18022} It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.{32237,30353} RvD4, at 10 ng/mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng/mouse, diminishes neutrophil infiltration in response to S. aureus infection.{30353} With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.{30353} It also promotes the clearance of apoptotic neutrophils by human fibroblasts.{30353}
Brand:CaymanSKU:- Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid (Item No. 90310).{18022} It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.{32237,30353} RvD4, at 10 ng/mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng/mouse, diminishes neutrophil infiltration in response to S. aureus infection.{30353} With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.{30353} It also promotes the clearance of apoptotic neutrophils by human fibroblasts.{30353}
Brand:CaymanSKU:- Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid (Item No. 90310).{18022} It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.{32237,30353} RvD4, at 10 ng/mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng/mouse, diminishes neutrophil infiltration in response to S. aureus infection.{30353} With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.{30353} It also promotes the clearance of apoptotic neutrophils by human fibroblasts.{30353}
Brand:CaymanSKU:- Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid (Item No. 90310).{18022} It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.{32237,30353} RvD4, at 10 ng/mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng/mouse, diminishes neutrophil infiltration in response to S. aureus infection.{30353} With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.{30353} It also promotes the clearance of apoptotic neutrophils by human fibroblasts.{30353}
Brand:CaymanSKU:- Resolvin D4 (RvD4) is a specialized pro-resolving mediator derived from docosahexaenoic acid (Item No. 90310).{18022} It has been detected in human milk, in the dorsal pouch of mice before and after infection with S. aureus, and in untreated tissues from humans, mice, and sardines.{32237,30353} RvD4, at 10 ng/mouse, reduces neutrophil infiltration in zymosan A-induced peritonitis and, at 200 ng/mouse, diminishes neutrophil infiltration in response to S. aureus infection.{30353} With isolated cells, RvD4 promotes phagocytosis of bacteria, opsonized zymosan A, and apoptotic neutrophils by human macrophages.{30353} It also promotes the clearance of apoptotic neutrophils by human fibroblasts.{30353}
Brand:CaymanSKU:-